- Home
- TAP vs ROIV Comparison
TAP vs ROIV Comparison
Compare TAP & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAP
- ROIV
- Stock Information
- Founded
- TAP 1873
- ROIV 2014
- Country
- TAP United States
- ROIV United Kingdom
- Employees
- TAP N/A
- ROIV N/A
- Industry
- TAP Beverages (Production/Distribution)
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- TAP Consumer Staples
- ROIV Health Care
- Exchange
- TAP Nasdaq
- ROIV Nasdaq
- Market Cap
- TAP 10.1B
- ROIV 8.6B
- IPO Year
- TAP N/A
- ROIV N/A
- Fundamental
- Price
- TAP $43.72
- ROIV $19.99
- Analyst Decision
- TAP Hold
- ROIV Strong Buy
- Analyst Count
- TAP 14
- ROIV 8
- Target Price
- TAP $53.43
- ROIV $21.06
- AVG Volume (30 Days)
- TAP 2.1M
- ROIV 8.0M
- Earning Date
- TAP 11-04-2025
- ROIV 11-10-2025
- Dividend Yield
- TAP 4.31%
- ROIV N/A
- EPS Growth
- TAP N/A
- ROIV N/A
- EPS
- TAP 5.06
- ROIV N/A
- Revenue
- TAP $11,283,200,000.00
- ROIV $23,233,000.00
- Revenue This Year
- TAP N/A
- ROIV N/A
- Revenue Next Year
- TAP $0.55
- ROIV $320.50
- P/E Ratio
- TAP $8.64
- ROIV N/A
- Revenue Growth
- TAP N/A
- ROIV N/A
- 52 Week Low
- TAP $42.94
- ROIV $8.73
- 52 Week High
- TAP $64.66
- ROIV $20.09
- Technical
- Relative Strength Index (RSI)
- TAP 31.99
- ROIV 86.17
- Support Level
- TAP $45.15
- ROIV $17.89
- Resistance Level
- TAP $47.24
- ROIV $18.96
- Average True Range (ATR)
- TAP 0.91
- ROIV 0.59
- MACD
- TAP -0.23
- ROIV 0.14
- Stochastic Oscillator
- TAP 17.03
- ROIV 97.67
About TAP Molson Coors Beverage Company Class B
Molson Coors owns well-known beer brands including Miller, Coors, Blue Moon, and Carling and ranks as the second-largest beer maker in both value and volume terms in the US, Canada, and the United Kingdom. Through licensing agreements, the firm also brews and distributes beer and hard seltzer under partner brands from Heineken, Anheuser-Busch InBev, Asahi, and Coca-Cola. The brewer uses independent distributors in the US, given the three-tier distribution requirements, while using a combination of distributors and an in-house sales team in Canada and Europe. North America remains its largest market, contributing over 80% of total revenue.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.